



- (51) **International Patent Classification:**
C07K 14/05 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2020/025069
- (22) **International Filing Date:**
26 March 2020 (26.03.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/824,080 26 March 2019 (26.03.2019) US
62/931,103 05 November 2019 (05.11.2019) US
62/969,569 03 February 2020 (03.02.2020) US
- (71) **Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 5th Floor, Oakland, CA 94607 (US).
- (72) **Inventors: PRUSSAK, Charles, E.;** C/o The Regents Of The University Of California, 1111 Franklin Street, 5th Floor, Oakland, CA 94607 (US). **KIPPS, Thomas, J.;**

C/o The Regents Of The University Of California, 1111 Franklin Street, 5th Floor, Oakland, CA 94607 (US). **WID-HOPF, George, F.;** C/o The Regents Of The University Of California, 1111 Franklin Street, 5th Floor, Oakland, CA 94607 (US). **OH, Christopher, S.;** C/o The Regents Of The University Of California, 1111 Franklin Street, 5th Floor, Oakland, CA 94607 (US).

- (74) **Agent: HETZER-EGGER, Claudia** et al.; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., 3580 Carmel Mountain Road, Suite 300, San Diego, CA 92130 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

- (54) **Title:** CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS




FIG. 13

- (57) **Abstract:** Provided herein is a chimeric antigen receptor (CAR) and CAR-expressing immune cells that target human ROR1 expressed aberrantly on a tumor cancers. Described herein are chimeric antigen receptors that target human ROR-1, cell compositions expressing the chimeric antigen receptors, and methods and uses of the chimeric antigen receptors and/or the cell compositions. The chimeric antigen receptors described herein can be expressed by the T lymphocytes isolated from an individual afflicted with cancer and re-administered to the individual.

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

05 November 2020 (05.11.2020)